By Mark De Belder2011-12-28T00:03:00
A new treatment available to combat valvular heart disease could be an opportunity to improve the care provided to those who would previously have been too ill for open heart surgery - and cut mortality rates in patients with the disease. Dr Mark De Belder explains.
With a HSJ subscription you’ll unlock:
HSJ is part of Wilmington Healthcare Limited. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud